Orexigen Therapeutics, Inc announced that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially...

Merck Inc announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the...

Flexion Therapeutics, Inc. will present positive clinical data from a post-hoc analysis of patients with unilateral knee osteoarthritis (OA) pain...

Alder BioPharmaceuticals announced new twelve-month data from its PROMISE 1 Phase III clinical trial of ALD 403 (eptinezumab) in episodic...

Eli Lilly and Company announced results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic...

Boston Scientific announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, multi-center study of...

Prothena Corporation plc has announced that the Company is discontinuing development of NEOD 001, an investigational antibody that was being...

AstraZeneca and MedImmune, its global biologics research and development arm, announced high-level results from the Phase III ARCTIC trial in...

Cancer genetic mutations not all treatable: System to rank relevance of mutations needed